Skip to content
10-Q

Quarterly Report

Five Prime Therapeutics, Inc.

0001564590-20-022885

← back to feed
Filed
May 7, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · May 5, 2020 36.64M sh
Capex Q1 2020 · Mar 31, 2020 $29K
Capex Q1 2020 · Mar 31, 2019 $983K
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$15.07M
Operating Cash Flow Q1 2020 · Mar 31, 2019 −$32.68M
Cash And Equivalents Q1 2020 · Mar 31, 2020 $67.69M
Cash And Equivalents Q1 2020 · Dec 31, 2019 $55.8M
Cash And Equivalents Q1 2020 · Mar 31, 2019 $29.63M
Cash And Equivalents Q1 2020 · Dec 31, 2018 $43.95M
Stockholders Equity Q1 2020 · Mar 31, 2020 $134.54M
Stockholders Equity Q1 2020 · Dec 31, 2019 $150.47M
Stockholders Equity Q1 2020 · Mar 31, 2019 $234.33M
Stockholders Equity Q1 2020 · Dec 31, 2018 $265.14M
Current Liabilities Q1 2020 · Mar 31, 2020 $19.21M
Current Liabilities Q1 2020 · Dec 31, 2019 $23.02M
Current Assets Q1 2020 · Mar 31, 2020 $150.29M
Current Assets Q1 2020 · Dec 31, 2019 $166.72M
Total Assets Q1 2020 · Mar 31, 2020 $202.97M
Total Assets Q1 2020 · Dec 31, 2019 $224.14M
Sga Expense Q1 2020 · Mar 31, 2020 $10.49M
Sga Expense Q1 2020 · Mar 31, 2019 $10.51M
Rd Expense Q1 2020 · Mar 31, 2020 $18.56M
Rd Expense Q1 2020 · Mar 31, 2019 $31.75M
Net Income Q1 2020 · Mar 31, 2020 −$20.12M
Net Income Q1 2020 · Mar 31, 2019 −$35.39M
Operating Income Q1 2020 · Mar 31, 2020 −$20.63M
Operating Income Q1 2020 · Mar 31, 2019 −$36.92M